Abstract:There has been little recent success in identifying novel analgesic drug targets and discovering better therapeutics for treating neuropathic pain. Existing analgesic drugs have significant safety, efficacy, tolerability and addiction concerns limiting their use. Recent studies have identified a critical ligand‐gated ion channel on peripheral sensory nerve fiber endings, transient receptor potential ankyrin 1 (TRPA1), as a promising novel analgesic target for treating neuropathic pain. TRPA1 is a validated analgesic target based upon TRPA1 knockout studies in established pain models, pharmacological studies with TRPA1 antagonists and human medical genetic data. Peripherally acting TRPA1 antagonists may provide a novel, safer and more effective option for treating neuropathic pain than existing analgesics. Utilizing a rational drug discovery approach, we have discovered a novel structural class of small molecule, reversible TRPA1 antagonists with excellent drug‐like features using a human TRPA1 fluorescence‐based intracellular calcium assay. Five potent antagonists, ALGX‐2513, ALGX‐2541, ALGX‐2563, ALGX‐2561 and ALGX‐2542, inhibited FFA agonist‐mediated responses with IC 50 s ranging from 23–65nM and were found to be highly selective (>100X) in assays for numerous related TRP channels. ALGX‐2437 and ALGX‐2513 inhibited AITC‐mediated TRPA1 calcium responses in isolated mouse dorsal root ganglion (DRG) neurons, confirming target engagement. In rat PK studies, dosing of ALGX‐2437 and ALGX‐2460 (30 mg/kg) produced robust in vivo drug exposure, achieving high C max values (5–10X IC 50 ) with t max values of 2 hr and t 1/2 values between 3–5 hrs. The analgesic effects of compounds in this series were evaluated in the spinal nerve ligation model (SNL) of neuropathic pain. A single dose (10–50mg/kg) of ALGX‐2437 showed dose‐dependent reversal (EC 50 = 25mg/kg) of mechanical hyperalgesia in the SNL pain model with a maximal possible efficacy (%MPE) of 79% at 2 hr post‐dosing (p<0.0001). Analysis of brain and blood levels showed low brain penetrance of the drug at all dose levels. No adverse behavioral effects, including impairment of rotarod performance, were observed at all doses. In addition, ALGX‐2460, ALGX‐2465 (30mg/kg) and ALGX‐2542 (10mg/kg) also inhibited mechanical allodynia in the SNL model with %MPE values of 38 to 65%. The effect of ALGX‐2542 (10mg/kg) was also evaluated in the paclitaxel chemotherapeutic‐induced neuropathic pain model and displayed similar efficacy in inhibiting mechanical hyperalgesia as observed in the SNL pain model. These results demonstrate Algomedix TRPA1 antagonists possess the requisite high potency, specificity, and pharmacokinetic properties to achieve substantial efficacy in multiple neuropathic pain models and hold promise as a new class of analgesic drugs for effectively and safely treating neuropathic pain patients. Support or Funding Information Supported by NIH grants 1R43DA031516 and 1R43AR065330 (JMH)

A Synthetic Cell-Penetrating Peptide Antagonizing Trka Function Suppresses Neuropathic Pain in Mice

Effects of TrkA Inhibitor IPTRK3 Pretreatment on Neuropathic Pain

Delayed Inhibition of ERK and P38 Attenuates Neuropathic Pain Without Affecting Motor Function Recovery after Peripheral Nerve Injury.

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Alleviating Neuropathic Pain Hypersensitivity by Inhibiting PKMζ in the Anterior Cingulate Cortex

Repurposing cell growth-regulating compounds identifies kenpaullone which ameliorates pathologic pain via normalization of inhibitory neurotransmission

Low affinity NGF receptor (p75 neurotrophin receptor) inhibitory antibody reduces pain behavior and CGRP expression in DRG in the mouse sciatic nerve crush model

MCRT, a Multifunctional Ligand of Opioid and Neuropeptide FF Receptors, Attenuates Neuropathic Pain in Spared Nerve Injury Model

The effect of intrathecal administration TRPA1 antagonists in a rat model of neuropathic pain.

Chemogenetics Modulation of Electroacupuncture Analgesia in Mice Spared Nerve Injury-Induced Neuropathic Pain through TRPV1 Signaling Pathway

Upregulation of NGF/TrkA-Related Proteins in Dorsal Root Ganglion of Paclitaxel-Induced Peripheral Neuropathy Animal Model

Phosphate NIMA-Related Kinase 2-Dependent Epigenetic Pathways in Dorsal Root Ganglion Neurons Mediates Paclitaxel-Induced Neuropathic Pain

Amelioration of Neuropathic Pain and Attenuation of Neuroinflammation Responses by Tetrahydropalmatine Through the p38MAPK/NF-κB/iNOS Signaling Pathways in Animal and Cellular Models

Intrathecal Administration of AS1928370, a Transient Receptor Potential Vanilloid 1 Antagonist, Attenuates Mechanical Allodynia in a Mouse Model of Neuropathic Pain

Intrathecal Administration of Cyclic AMP Response Element-Binding Protein-Antisense Oligonucleotide Attenuates Neuropathic Pain after Peripheral Nerve Injury and Decreases the Expression of N-methyl-D-aspartic Receptors in Mice.

Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain

Ketamine depresses toll-like receptor 3 signaling in spinal microglia in a rat model of neuropathic pain.

A Novel Class of Potent, Allosteric Trpa1 Antagonists Reverse Hyperalgesia in Multiple Rat Models of Neuropathic Pain

Triptolide Alleviates Neuropathic Pain by Inhibiting the Activation of Microglial Toll-Like Receptor 3.

Neuropilin-1 is a co-receptor for NGF and TrkA-evoked pain

Resolving TRPV1- and TNF-α-mediated Spinal Cord Synaptic Plasticity and Inflammatory Pain with Neuroprotectin D1.